semaglutide alcohol use disorder clinical trial as a promising new treatment for GLP-1 Drug Semaglutide Substantially Reduced

Key highlights: Average weight loss of ~12.4% in Phase 3 trials Improvements in blood pressure, triglycerides, and waist circumference Oral formulation could significantly expand accessibility and patient adoption Approved for adults with obesity or overweight plus weight-related conditions This approval represents another major shift in the rapidly growing obesity therapeutics market and increases competition with injectable treatments like Wegovy

Free assessment Start with some quick questions about your health history and goals to see if youre eligible for same-day approval

Schedule your free consultation or call (954) 441-3962 to learn more and schedule an evaluation to determine which weight loss treatment may be appropriate for you.

J.HolfordN